Rhumbline Advisers Grows Holdings in Syndax Pharmaceuticals, Inc. $SNDX

Rhumbline Advisers increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 6.5% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 120,810 shares of the company’s stock after buying an additional 7,361 shares during the period. Rhumbline Advisers owned 0.14% of Syndax Pharmaceuticals worth $1,484,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Syndax Pharmaceuticals by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company’s stock valued at $706,000 after acquiring an additional 1,811 shares in the last quarter. Quarry LP purchased a new stake in Syndax Pharmaceuticals during the 1st quarter valued at $25,000. DAFNA Capital Management LLC boosted its holdings in shares of Syndax Pharmaceuticals by 0.5% during the 1st quarter. DAFNA Capital Management LLC now owns 544,502 shares of the company’s stock valued at $6,689,000 after acquiring an additional 2,500 shares during the last quarter. E Fund Management Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 27.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 16,031 shares of the company’s stock valued at $197,000 after acquiring an additional 3,428 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Syndax Pharmaceuticals by 2.5% during the 1st quarter. Bank of New York Mellon Corp now owns 229,758 shares of the company’s stock valued at $2,823,000 after acquiring an additional 5,497 shares during the last quarter.

Insider Transactions at Syndax Pharmaceuticals

In other news, Director Dennis Podlesak sold 19,200 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.84, for a total transaction of $304,128.00. Following the sale, the director directly owned 191,763 shares of the company’s stock, valued at $3,037,525.92. The trade was a 9.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Metzger sold 157,307 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $16.41, for a total value of $2,581,407.87. Following the sale, the chief executive officer owned 298,661 shares in the company, valued at approximately $4,901,027.01. The trade was a 34.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 204,537 shares of company stock worth $3,265,935 in the last 90 days. Insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Trading Up 4.7%

Shares of SNDX stock opened at $15.45 on Friday. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $22.50. The company has a market cap of $1.33 billion, a PE ratio of -3.97 and a beta of 0.72. The company has a debt-to-equity ratio of 2.06, a current ratio of 4.71 and a quick ratio of 4.55. The stock’s 50 day simple moving average is $13.39 and its two-hundred day simple moving average is $12.03.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.18. The company had revenue of $37.96 million for the quarter, compared to analyst estimates of $26.64 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The firm’s revenue for the quarter was up 984.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.80) EPS. Research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. BTIG Research raised their price target on shares of Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Stifel Nicolaus initiated coverage on shares of Syndax Pharmaceuticals in a report on Wednesday, September 10th. They issued a “buy” rating and a $44.00 price objective on the stock. B. Riley raised shares of Syndax Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 6th. Citigroup lifted their price target on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Finally, The Goldman Sachs Group lifted their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Syndax Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $39.22.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).